Cargando…

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition

Peroxisome proliferator-activated receptors (PPARs) play crucial roles in glucose and lipid metabolism and inflammation. Sanguinarine is a natural product that is isolated from Sanguinaria Canadensis, a potential therapeutic agent for intervention in chronic diseases. In this study, biochemical and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Siyu, Wang, Rui, Chen, Shuming, He, Jialing, Zheng, Weili, Li, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512631/ https://www.ncbi.nlm.nih.gov/pubmed/34641558 http://dx.doi.org/10.3390/molecules26196012

Ejemplares similares

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Nutraceuticals as Ligands of PPARγ
por: Penumetcha, Meera, et al.
Publicado: (2012)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Effects of PPARγ Ligands on Leukemia
por: Tabe, Yoko, et al.
Publicado: (2012)

Gastrointestinal Cytoprotection by PPARγ Ligands
por: Naito, Yuji, et al.
Publicado: (2010)

PPARα/γ-Independent Effects of PPARα/γ Ligands on Cysteinyl Leukotriene Production in Mast Cells
por: Yamashita, Masamichi
Publicado: (2008)

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia
por: Balakumar, Pitchai, et al.
Publicado: (2019)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro
por: Yi, Wei, et al.
Publicado: (2017)

Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency
por: Zheng, Weili, et al.
Publicado: (2015)

Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-γ Agonists
por: Gurley, Catherine, et al.
Publicado: (2008)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Clinical Use of PPARγ Ligands in Cancer
por: Hatton, Jennifer L., et al.
Publicado: (2008)

An alternate binding site for PPARγ ligands
por: Hughes, Travis S., et al.
Publicado: (2014)

Ligand Modulated Antagonism of PPARγ by Genomic and Non-Genomic Actions of PPARδ
por: Gustafsson, Mattias C. U., et al.
Publicado: (2009)

Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists
por: Irwin, Sean, et al.
Publicado: (2022)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Structural Basis for the Regulation of PPARγ Activity by Imatinib
por: Jang, Jun Young, et al.
Publicado: (2019)

Kernel learning for ligand-based virtual screening: discovery of a new PPARγ agonist
por: Rupp, Matthias, et al.
Publicado: (2010)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation
por: Jang, Jun Young, et al.
Publicado: (2019)

Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode
por: Capelli, Davide, et al.
Publicado: (2016)

Synthesis of Phthalimide Derivatives as Potential PPAR-γ Ligands
por: Eom, So Hyeon, et al.
Publicado: (2016)

Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands
por: Choi, Jang Hyun, et al.
Publicado: (2010)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9ve16qnsphtchl8cbet0tlfrma